FURI

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Antimalarial medication, Research, FURI, Congress, Conference, Biotechnology, TIMM, Aspergillosis, GSK, Sale, Mucorales, LAMB, National Institutes of Health, NIH, Trial of the century, IND, AAAM, Investment, Data analysis, Medical Mycology, Pharmaceutical industry

“SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.

Key Points: 
  • “SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.
  • In March 2023, SCYNEXIS and GSK entered into an exclusive license agreement for the development, manufacturing and commercialization of ibrexafungerp (BREXAFEMME).
  • Presented preclinical data on SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) held in Athens, Greece October 20-23, 2023.
  • Cash, cash equivalents and investments totaled $98.0 million on December 31, 2023, compared to $73.5 million on December 31, 2022.

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
NDA, Security (finance), IND, Investment, Risk, GSK plc, Tablet, Biotechnology, Hansoh Pharmaceutical, Mucorales, VVC, Research, Data analysis, Medical Mycology, Antimalarial medication, FDA, FURI, GSK, Candidiasis, NIH, TIMM, Phase, Congress, Candida auris, Cryptocurrency, Pharmaceutical industry, Beauty salon

Under the agreement, SCYNEXIS has received the $90 million upfront payment as well as the first development milestone of $25 million.

Key Points: 
  • Under the agreement, SCYNEXIS has received the $90 million upfront payment as well as the first development milestone of $25 million.
  • SCYNEXIS became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp.
  • Cash, cash equivalents and investments totaled $105.2 million on September 30, 2023, compared to $73.5 million on December 31, 2022.
  • Based upon the company’s current operating plan, SCYNEXIS believes that its existing cash, cash equivalents and investments provides a cash runway beyond two years.

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
Workforce, Mucorales, GSK, Hansoh Pharmaceutical, IV, SG, Ibrexafungerp, General Administration of Sport of China, Biotechnology, NDA, NIH, Candidiasis, Global health, Tablet, End-user license agreement, Silicon, Congress, Antimalarial medication, ECCMID, VVC, Investment, European, License, Research, IND, NMPA, Infection, Auris, FURI, Pharmaceutical industry, Cryptocurrency

JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.
  • On June 21, 2023, SCYNEXIS announced the achievement of a $25 million performance-based development milestone under its exclusive license agreement with GSK for ibrexafungerp.
  • Selling, general & administrative (SG&A) expense for Q2 2023 decreased to $7.5 million from $15.8 million for Q2 2022.
  • Total other income was $5.7 million for Q2 2023, versus total other income of $8.4 million for Q2 2022.

SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023
Workforce, GSK, FURI, Medical Affairs Bureau, Candidiasis, Partnership, SG, General Administration of Sport of China, Biotechnology, Voriconazole, Tablet, End-user license agreement, Congress, GSK plc, Antimalarial medication, ECCMID, Investment, Patient, European, License, Commercial, Research, Fluconazole, Infection, Safety, Salvage therapy, Pharmaceutical industry, Beauty salon

JERSEY CITY, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • JERSEY CITY, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced financial results for the first quarter ended March 31, 2023.
  • On March 30, 2023, SCYNEXIS announced that the Company has entered into an exclusive agreement with GSK to commercialize and further develop BREXAFEMME® (ibrexafungerp tablets) for all indications.
  • BREXAFEMME net sales were $1.1 million in first quarter 2023 and $0.7 million in Q1 2022.
  • Cash, cash equivalents and short-term investments totaled $54.8 million on March 31, 2023, compared to $73.5 million on December 31, 2022.

SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark

Retrieved on: 
Thursday, April 13, 2023
Urinary tract infection, Infection, Biotechnology, Candida auris, Congress, Antimalarial medication, ECCMID, European, FURI, Pharmaceutical industry

surveillance)

Key Points: 
  • surveillance)
    Poster Session 6D: Antifungal drugs & treatment (incl.
  • clinical trials)
    Poster Session 6D: Antifungal drugs & treatment (incl.
  • clinical trials)
    Poster Session 6D: Antifungal drugs & treatment (incl.
  • clinical trials)

SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 31, 2023
Candidiasis, Public, Food and Drug Administration, Prescription, Bangladesh Technical Education Board, Chemistry, Incidence, Journal, Candida auris, Investment, Patient, Body mass index, Medicines and Healthcare products Regulatory Agency, 3B, Infection, Research, VVC, Ibrexafungerp, Diagnosis, Fungal infection, FDA, NIH, Safety, Salvage therapy, Aspergillosis, GSK, General Administration of Sport of China, Biotechnology, Voriconazole, Tablet, Mortality, Hand, MHRA, Journal of Fungi, SG, CMC, IC, NDA, Medication, Case Western Reserve University, Fungemia, Antimalarial medication, United Kingdom, Poster, Trial of the century, Fluconazole, Food, Pharmaceutical industry, Drug, Self storage, Cryptocurrency, Reinsurance, Fungus, IQVIA, FURI

GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.

Key Points: 
  • GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.
  • JERSEY CITY, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2022.
  • According to IQVIA data, there were 5,125 total prescriptions for BREXAFEMME written in Q4 2022, and more than 20,000 total prescriptions written in 2022.
  • The approval was based on positive results from the pivotal Phase 3 CANDLE study reported in February 2022.

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

Retrieved on: 
Thursday, November 17, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tablet, Shanda, Mycosis, European Medicines Agency, WHO, Public health, Auris, Infection, Food, Biomedical Advanced Research and Development Authority, IC, EMA, IA, Biotechnology, BAA, Candida auris, Patient, QIDP, Candidiasis, Broad Agency Announcement, Aspergillus fumigatus, FURI, World Health Organization, Mucorales, News, BID, Fungemia, Fungus, Development, CBRN, Canker, IV, Drug of last resort, New Drug Application, MCM, PDUFA, FDA, Antibiotics, Pharmaceutical industry

For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.

Key Points: 
  • For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.
  • It is extremely exciting to see BARDA announce increased emphasis on fighting dangerous fungal pathogens, said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS.
  • Ibrexafungerp, with its promising activity against multiple drug resistant and often-deadly fungal infections, has enormous potential to benefit patients with severe fungal disease and limited treatment options.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi

Retrieved on: 
Monday, November 7, 2022
VVC, Public health, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mortality, Research, Antifungal, Journal, IV, Food, EMA, Infection, Mucorales, Biotechnology, Fungemia, GLOBE, IA, FDA, WHO, Journal of Fungi, Tablet, QIDP, Review, Voriconazole, Immunodeficiency, PDUFA, Canker, NASDAQ, FURI, IC, Patient, Candidiasis, Pharmaceutical industry, Fungus

This review in the Journal of Fungi showcases ibrexafungerp as a potential treatment for invasive mold infections, which are a growing threat to public health, particularly in immunocompromised patients, said David Angulo, M.D., Chief Medical Officer of SCYNEXIS and lead author of the publication.

Key Points: 
  • This review in the Journal of Fungi showcases ibrexafungerp as a potential treatment for invasive mold infections, which are a growing threat to public health, particularly in immunocompromised patients, said David Angulo, M.D., Chief Medical Officer of SCYNEXIS and lead author of the publication.
  • In the article, authors describe the need for novel treatment strategies to improve outcomes of difficult-to-treat invasive mold infections, as currently available treatments are limited, resistance against current antifungals is common and mortality remains high.
  • Two ongoing clinical trials will provide further insight into the potential of ibrexafungerp for the treatment of invasive mold infections.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

Retrieved on: 
Monday, October 24, 2022
European Medicines Agency, Candida glabrata, PDUFA, Fungus, Birth, Shanda, IA, Nausea, Population, Diagnosis, New Drug Application, EMA, Infection, QIDP, Candidiasis, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Biotechnology, Diarrhea, IV, Abdominal pain, Chronic mucocutaneous candidiasis, IC, Salvage therapy, Most, Mortality, FURI, Food, VVC, Vomiting, Medical Affairs Bureau, Administration, Pipeline, Incidence, Fungemia, Mycosis, Survival, GLOBE, Canker, Death, FDA, Drug of last resort, Tablet, Pregnancy, ID, CYP3A, Dizziness, Poster, Pharmaceutical industry, Dietary supplement

All-cause mortality analysis shows 94.6% survival 30 days post-therapy in patients with invasive candidiasis or candidemia who were treated with ibrexafungerp.

Key Points: 
  • All-cause mortality analysis shows 94.6% survival 30 days post-therapy in patients with invasive candidiasis or candidemia who were treated with ibrexafungerp.
  • The analyses were presented during IDWeek 2022 held in Washington, D.C., October 19-23, 2022.
  • The data presented includes 113 patients enrolled in the FURI study who had completed treatment through October 2021.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal

Retrieved on: 
Thursday, October 20, 2022
CFO, Candida auris, Growth, Candidiasis, NASDAQ, Patient, Biotechnology, IV, Auris, Partnership, FURI, VVC, Company, Industry, PBM, Board, CEO, Mycosis, EDT, GLOBE, Director, Drug of last resort, Tablet, Prescription, Leadership, Pharmaceutical industry, Airline, Management, Perfume

During this process, SCYNEXIS will wind down its promotional activities, while keeping BREXAFEMME on the market and available to patients.

Key Points: 
  • During this process, SCYNEXIS will wind down its promotional activities, while keeping BREXAFEMME on the market and available to patients.
  • SCYNEXIS will conclude the partnership with its contracted commercial sales partner, Amplity Health, and will undertake a workforce reduction.
  • SCYNEXIS is announcing changes to its executive leadership team:
    Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will retire as of December 31, 2022.
  • During this process, SCYNEXIS will wind down its promotional activities, while keeping BREXAFEMME on the market and available to patients.